Zydus Lifesciences Transcripts 31st AGM Held on August 11, 2026
Zydus Lifesciences Limited held its 31st AGM on August 11, 2026. Consolidated revenues for FY2025-26 were ₹271.5 billion (₹27,150 crore), a 17% increase. The company announced a share buyback of up to ₹1,100 crore at ₹1,260 per share. A dividend of ₹1 per share was declared. The AGM also covered financial statements, director appointments, and business updates.
The AGM transcript provides updates on financial performance, strategic initiatives, and corporate actions like a share buyback. This information is material for investors and impacts their understanding of the company's direction and value.
The announcement is a transcript of an AGM, which is a routine event. While it contains financial performance details and future plans, it doesn't introduce significantly new or unexpected information that would strongly sway sentiment.
Zydus Lifesciences Limited has released the transcript of its 31st Annual General Meeting (AGM) held on Tuesday, August 11, 2026. The AGM, conducted virtually, saw the participation of the Board of Directors and Key Managerial Personnel, including Chairman Mr. Pankaj R. Patel and Managing Director Dr. Sharvil P. Patel.
During the meeting, the integrated annual report for the year ended March 31, 2026, was presented, highlighting the company's financial performance, ESG initiatives, and commitment to transparency and sustainability. Key business segments discussed included Saroglitazar Magnesium (Lipaglyn® and Bilypsa®), which treated nearly 4 million patients in 2025, and Tishtha®, a nivolumab biosimilar that has reached over 25,000 cancer patients in India.
Financially, consolidated revenues for FY2025-26 reached ₹271.5 billion (₹27,150 crore), a 17% growth over the previous year, with an EBITDA margin of 31.2%. The company also announced a share buyback of up to ₹1,100 crore at ₹1,260 per share.
The AGM agenda included the adoption of standalone and consolidated financial statements for FY2025-26, declaration of a dividend of ₹1 per share, re-appointment of directors, ratification of cost auditors' remuneration, and approval for the appointment of Mr. Kulin Lalbhai as an additional independent director. The company also discussed its R&D investments, global market presence, MedTech expansion, and sustainability efforts, including aiming for net water neutrality by 2028.
A plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.